FDA accepts Loxo approval application for biomarker-driven cancer drug
If approved, LOXO-101 (larotrectinib) would be the second drug to win a biomarker-based label, after Merck's Keytruda.
If approved, LOXO-101 (larotrectinib) would be the second drug to win a biomarker-based label, after Merck's Keytruda.
A new report shows a steady growth in so-called "basket studies" in oncology, along with growing interest by the drug industry.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Loxo's data highlight growing industry interest in so-called "basket" trials and drugs that targeted to genetic markers instead of tumor types.